| abstract |
The invention relates to cholesteryl ester-transferring protein inhibitors of the formula to their prodrugs or pharmaceutically acceptable salts of the compounds and prodrugs, to the use of inhibitors for increasing levels of certain plasma lipids, including high density lipoprotein (HDL) cholesterol, and for lowering levels of certain other plasma lipids such as low density lipoprotein (LDL) cholesterol and triglycerides. The compounds are used to treat diseases that are affected by low levels of HDL-cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some animals and the human. |